#USA #Princeton #Soligenix #HyBryte #Tomas Philipson

Soligenix Welcomes Dr. Tomas J. Philipson as Strategic Advisor

Soligenix, Inc., a late-stage biopharmaceutical company, announced the appointment of Dr. Tomas J. Philipson as a strategic advisor. Dr. Philipson's experience, especially in health care policy and U.S. economic policy, will bring significant insight into Soligenix’s endeavors, particularly its ongoing projects centered on rare diseases with unmet medical needs.

Dr. Philipson is well-recognized in the landscape of U.S. healthcare policy, frequently appearing in major media outlets like The New York Times and CNN. He is currently the managing partner of MEDA Ventures, having co-founded multiple companies, including Precision Health Economics LLC.

During his tenure in the government, Dr. Philipson served in a leadership capacity on President Trump’s White House Council of Economic Advisers from 2017 to 2020 and contributed significantly to various healthcare initiatives, including the Biden Cancer Initiative.

Christopher J. Schaber, Soligenix's President and CEO, expressed his enthusiasm for Dr. Philipson joining the team, emphasizing that his extensive network and knowledge will support the company’s innovative products aimed at addressing rare diseases. One of the key products in development is HyBryte™, currently undergoing a Phase 3 clinical trial. This promising treatment utilizes photodynamic therapy to target cutaneous T-cell lymphoma (CTCL) effectively.

About HyBryte™
HyBryte™ (research name SGX301) stands out as an innovative treatment option, employing safe, visible light in its application. Its active ingredient, synthetic hypericin, is absorbed by malignant T-cells in skin lesions, activating the treatment 24 hours post-application. The advantage of using visible light lies in its deeper skin penetration compared to UV light, potentially leading to more effective treatment of skin ailments without the carcinogenic risks associated with traditional drugs.

In previous clinical studies, HyBryte™ demonstrated statistically significant improvements in patients with CTCL, solidifying its position as a future-first-line therapy for this rare skin cancer. The FDA and EMA have recognized HyBryte™ as an orphan drug and fast-track candidate, underscoring its importance in treating a disease that currently lacks effective treatments.

The ongoing FLASH clinical trial, which successfully enrolled 169 patients, displayed significant results in lesion reduction, with subsequent treatment cycles showing robust response rates, particularly among patients treated for longer durations.

With the FDA noting that a second successful Phase 3 trial is necessary for marketing approval, Soligenix anticipates launching FLASH2 before the end of 2024. This follow-up study will expand upon the first, maintaining similar structures while extending the treatment cycle duration.

As Soligenix strives towards regulatory approvals for HyBryte™, it remains committed to innovating healthcare solutions for diseases that have been overlooked and underserved. The appointment of Dr. Philipson heralds a new chapter for the company, as it leverages his wealth of knowledge and industry connections to boost its healthcare innovations to market.

For more information on Soligenix and HyBryte™, visit their website and follow their latest updates on social media.